Aarti Pharmalabs Ltd inaugurates its new state-of-the-art additional manufacturing block at Tarapur Unit 5

Aarti Pharmalabs Ltd has inaugurated an additional manufacturing block located at Tarapur, MIDC, Plot No. L-28/29/99. The company has successfully obtained all the necessary permissions and approvals to start the facility. This block has a total capacity of 3600 TPA for Xanthine derivatives manufacturing, taking our total capacity to 9600 TPA, thereby placing us amongst top 3 Xanthine derivatives manufacturers globally.

Commenting on this milestone, Mr. Rashesh Gogri, Chairman of Aarti Pharmalabs, said: "This is a significant milestone which represents a big leap forward for our company, expanding our production capabilities and strengthening our ability to serve our business partners. Trial production has been initiated, and the facility will be ramped up for optimum utilization in the next few quarters."

The inauguration event witnessed the presence of the Senior Management team, alongside the dedicated members of the Aarti Pharmalabs team. This new manufacturing block emphasizes a commitment towards the company's growth and capability development to cater to large customers' needs.

Shares of Aarti Pharmalabs Limited was last trading in BSE at Rs. 681.15 as compared to the previous close of Rs. 675.00. The total number of shares traded during the day was 12731 in over 627 trades.

The stock hit an intraday high of Rs. 694.00 and intraday low of 676.00. The net turnover during the day was Rs. 8748279.00.

Source : Equity Bulls

Keywords

AartiPharmalabs INE0LRU01027 Pharmaceuticals Stateoftheart ManufacturingBlock Tarapur Unit5